PolyPid (PYPD NASDAQ) stock market data APIs
$3.554
0.05(1.4%)
as of June 30, 2025
Try our APIs with
free plan!
PolyPid Financial Data Overview
Price chart is built with
Anychart
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Prev. Close
3.554
Open
3.603
High
3.6152
Low
3.4287
52 wk Range
2.3-4.42
Market Cap
36 382 K
Shares Outstanding
10 191 K
EPS
-0.7
Beta
1.25
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PolyPid data using free add-ons & libraries
Get PolyPid Fundamental Data
PolyPid Fundamental data includes:
- Net Revenue:
- EBITDA: -27 735 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-14
- EPS/Forecast: -0.82
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PolyPid News
New
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
Big names may rule the headlines, but many of the market’s future stars begin as under-the-radar underdogs. While Wall Street focuses on the trillion-dollar club – think the ‘Magnificent 7’ �...
PolyPid stock price target lowered to $14 at JMP on warrant dilution
JMP Securities lowered its price target on PolyPid Ltd. (NASDAQ:PYPD) to $14 from $16 on Monday, while maintaining its Market Outperform rating on the stock. The micro-cap biotech company, currently...
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (FDA) Approval of D-PLEX ‚ ‚€ ‚€.The Co...
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
The Company Anticipates that with this Additional Funding, PolyPid’s Runway would be Extended beyond Anticipated U.S. Food and Drug Administration (“FDA”) Approval of D-PLEX₁₀₀.The Company...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
